title: Review article: the natural history of paediatric-onset ulcerative colitis in population-based studies.
abstract: BACKGROUND
  A better knowledge of the natural history of disabling chronic diseases is essential to improve patient management, evaluate the impact of treatment strategies and provide predictors for disabling disease and comprehensive information for patients.
  
  
  OBJECTIVE
  To summarise our current knowledge issued from population-based studies of the natural history of ulcerative colitis (UC) in children.
  
  
  METHODS
  We searched MEDLINE (source PubMed) and international conference abstracts, and included all population-based studies that evaluated long-term outcome of paediatric-onset (<17 years at diagnosis) UC.
  
  
  RESULTS
  A total of 26 population-based studies were considered in this review from the total of 61 articles or abstracts screened. Most patients presented disease extension and about two-thirds of patients had pancolitis at the end of follow-up. One-half of patients experienced extra-intestinal manifestations and primary sclerosing cholangitis was observed in 5-10% of patients. Overall, patients did not appear to have any significant growth retardation or delayed puberty. About two-thirds of patients required corticosteroid therapy and up to 25% were steroid dependent. An increased use of thiopurines was observed and the most recent data indicate that up to one-half of patients were exposed to thiopurines and 10-30% were exposed to anti-tumour necrosis factor. One-half of patients required hospitalisations and 20% of patients required colectomy after a follow-up of 10 years.
  
  
  CONCLUSIONS
  Paediatric-onset UC is characterised by a high rate of disease extension. About 20% of patients had been operated at 10-year follow-up. New population-based studies are needed to evaluate the impact of new treatment strategies comprising immunosuppressants and biologics.
authors.affiliation: Gastroenterology Unit, Epimad Registry, Amiens University Hospital, Université de Picardie Jules Verne, Amiens, France.
authors.forename: M
authors.initials: M
authors.lastname: Fumery
authors.affiliation: Department of Gastroenterology, Univerzity Karlovy, Prague, Czech Republic.|EPICOM, European Crohn & Colitis Organization, Vienna, Austria.
authors.forename: D
authors.initials: D
authors.lastname: Duricova
authors.affiliation: EPICOM, European Crohn & Colitis Organization, Vienna, Austria.|Public Health, Epidemiology and Economic Health, Epimad Registry, Maison Régionale de la Recherche Clinique, Centre Hospitalier Universitaire Régional, 59037, Lille Cedex, France.|Lille Inflammation Research International Center LIRIC - UMR 995 Inserm/Université Lille 2/CHRU de Lille, Equipe IBD and Environmental Factors: Epidemiology and Functional Analyses, Lille University, Lille, France.
authors.forename: C
authors.initials: C
authors.lastname: Gower-Rousseau
authors.affiliation: EPICOM, European Crohn & Colitis Organization, Vienna, Austria.|Division of Gastroenterology, AOU Careggi Hospital, Florence, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Annese
authors.affiliation: Gastroenterology, Inserm U954, University Hospital of Nancy-Brabois, Université Henri Poincaré, Vandoeuvre-lès-Nancy, France.
authors.forename: L
authors.initials: L
authors.lastname: Peyrin-Biroulet
authors.affiliation: EPICOM, European Crohn & Colitis Organization, Vienna, Austria.|1st Department of Medicine, Semmelweis University, Budapest, Hungary.
authors.forename: P L
authors.initials: PL
authors.lastname: Lakatos
mesh_terms: D000305:Adrenal Cortex Hormones; D003082:Colectomy; D003093:Colitis, Ulcerative / Q000453:epidemiology* / Q000503:physiopathology* / Q000628:therapy; D019468:Disease Management; D018450:Disease Progression; D006801:Humans
chemical_list: D000305:Adrenal Cortex Hormones